1-20 of 28
Ursula A. Matulonis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Ryan B. Corcoran, Khanh T. Do, Jeong E. Kim, James M. Cleary, Aparna R. Parikh, Oladapo O. Yeku, Niya Xiong, Colin D. Weekes, Jennifer Veneris, Leanne G. Ahronian, Gianluca Mauri, Jun Tian, Bryanna L. Norden, Alexa G. Michel, Emily E. Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J. Fetter, Joan S. Brugge, Helen Chen, Naoko Takebe, Richard T. Penson, Dejan Juric, Keith T. Flaherty, Ryan J. Sullivan, Jeffrey W. Clark, Rebecca S. Heist, Ursula A. Matulonis, Joyce F. Liu, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (9): 1739–1749.
https://doi.org/10.1158/1078-0432.CCR-23-3135
Published: 01 May 2024
View article titled, Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
Open the PDF for Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract B013: Folate receptor alpha (FRa) expression and correlation with other molecular alterations in high grade serous endometrial cancer (EC)

Rebecca L. Porter, Sandy Elias, Niya Xiong, Madeline Polak, Kayla Fahey, Nabihah Tayob, Courtney Qi, Carina Feeney, Swati Narayan, Jennifer Curtis, Susana Campos, Carolyn Krasner, Elizabeth Lee, Elizabeth Stover, Alexi A. Wright, Joyce F. Liu, Ursula A. Matulonis, Panagiotis Konstantinopoulos
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (5_Supplement): B013.
https://doi.org/10.1158/1557-3265.ENDO24-B013
Published: 01 March 2024
View article titled, Abstract B013: Folate receptor alpha (FRa) expression and correlation with other molecular alterations in high grade serous endometrial cancer (EC)
Journal Articles

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

Felipe Batalini, Doga C. Gulhan, Victor Mao, Antuan Tran, Madeline Polak, Niya Xiong, Nabihah Tayob, Nadine M. Tung, Eric P. Winer, Erica L. Mayer, Stian Knappskog, Per E. Lønning, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos, David B. Solit, Helen Won, Hans P. Eikesdal, Peter J. Park, Gerburg M. Wulf
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (21): 4714–4723.
https://doi.org/10.1158/1078-0432.CCR-22-0749
Published: 01 November 2022
View article titled, Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
Open the PDF for Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers in another window
Includes: Supplementary data
Journal Articles

Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

Min Liu, Nabihah Tayob, Livius Penter, MacLean Sellars, Anna Tarren, Vipheaviny Chea, Isabel Carulli, Teddy Huang, Shuqiang Li, Su-Chun Cheng, Phuong Le, Laura Frackiewicz, Julia Fasse, Courtney Qi, Joyce F. Liu, Elizabeth H. Stover, Jennifer Curtis, Kenneth J. Livak, Donna Neuberg, Guanglan Zhang, Ursula A. Matulonis, Catherine J. Wu, Derin B. Keskin, Panagiotis A. Konstantinopoulos
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3356–3366.
https://doi.org/10.1158/1078-0432.CCR-21-2834
Published: 02 August 2022
View article titled, Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Open the PDF for Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

Felipe Batalini, Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley, Geoffrey I. Shapiro, Viktor Adalsteinsson, Eric P. Winer, Panagiotis A. Konstantinopoulos, Alan D'Andrea, Elizabeth M. Swisher, Ursula A. Matulonis, Gerburg M. Wulf, Erica L. Mayer
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1493–1499.
https://doi.org/10.1158/1078-0432.CCR-21-3045
Published: 14 April 2022
View article titled, Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
Open the PDF for Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract PR06: Dissecting mechanisms of replication fork stabilization in patient-derived high-grade serous organoid cultures and their impact on therapeutic sensitivity and the immune-tumor interaction

Sarah J. Hill, Patrick Lizotte, Nikolas Kesten, Neil S. Horowitz, Michael G. Muto, Michael J. Worley, Colleen M. Feltmate, Ross S. Berkowitz, Henry Long, Ursula A. Matulonis, Christopher P. Crum, Myles Brown, Alan D. D'Andrea
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): PR06.
https://doi.org/10.1158/1557-3265.OVCA19-PR06
Published: 01 July 2020
View article titled, Abstract PR06: Dissecting mechanisms of replication fork stabilization in patient-derived high-grade serous organoid cultures and their impact on therapeutic sensitivity and the immune-tumor interaction
Journal Articles

Abstract A73: BCL-XL dependency in a subset of ovarian clear-cell carcinoma cell lines

Elizabeth H. Stover, Maya K. Gelbard, Ursula A. Matulonis, Matthew Meyerson
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): A73.
https://doi.org/10.1158/1557-3265.OVCA19-A73
Published: 01 July 2020
View article titled, Abstract A73: BCL-XL dependency in a subset of ovarian clear-cell carcinoma cell lines
Journal Articles

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Amit M. Oza, Ursula A. Matulonis, Angeles Alvarez Secord, John Nemunaitis, Lynda D. Roman, Sarah P. Blagden, Susana Banerjee, William P. McGuire, Sharad Ghamande, Michael J. Birrer, Gini F. Fleming, Merry Jennifer Markham, Hal W. Hirte, Diane M. Provencher, Bristi Basu, Rebecca Kristeleit, Deborah K. Armstrong, Benjamin Schwartz, Patricia Braly, Geoff D. Hall, Kenneth P. Nephew, Simone Jueliger, Aram Oganesian, Sue Naim, Yong Hao, Harold Keer, Mohammad Azab, Daniela Matei
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (5): 1009–1016.
https://doi.org/10.1158/1078-0432.CCR-19-1638
Published: 02 March 2020
View article titled, A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Open the PDF for A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract NT-101: QUADRA: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE SINGLE-AGENT NIRAPARIB TREATMENT IN PATIENTS WITH RELAPSED OVARIAN CANCER (ROC) WHO HAVE RECEIVED ≥3 PRIOR CHEMOTHERAPY REGIMENS

Kathleen Moore, Angeles Secord, Melissa Geller, David Miller, Noelle Cloven, Gini Fleming, Andrea E. Wahner Hendrickson, Masoud Azodi, Paul Disilvestro, Amit Oza, Mihaela Cristea, Jonathan S. Berek, John Chan, Yong Li, Kaiming Sun, Katarina Luptakova, Ursula A. Matulonis, Bradley J. Monk
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22_Supplement): NT-101.
https://doi.org/10.1158/1557-3265.OVCASYMP18-NT-101
Published: 15 November 2019
View article titled, Abstract NT-101: QUADRA: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE SINGLE-AGENT NIRAPARIB TREATMENT IN PATIENTS WITH RELAPSED OVARIAN CANCER (ROC) WHO HAVE RECEIVED ≥3 PRIOR CHEMOTHERAPY REGIMENS
Journal Articles

Abstract AP22: DNA DAMAGE RESPONSES AND IMMUNE PROFILING THROUGH HIGHLY MULTIPLEXED TISSUE IMMUNOFLUORESCENCE (T-CYCIF) IN HIGH-GRADE SEROUS OVARIAN CANCER

Anniina Färkkilä, Jia-Ren Lin, Zoltan Maliga, Sameer S. Chopra, Bose Koruchupakkal, Brooke E. Howitt, Kyle C. Strickland, Sandro Santagata, Elizabeth M. Swisher, Ursula A. Matulonis, Jennifer. L. Guerriero, Kevin Elias, Panagiotis Konstantinopoulos, Peter K. Sorger, Alan D. D'Andrea
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22_Supplement): AP22.
https://doi.org/10.1158/1557-3265.OVCASYMP18-AP22
Published: 15 November 2019
View article titled, Abstract AP22: DNA DAMAGE RESPONSES AND IMMUNE PROFILING THROUGH HIGHLY MULTIPLEXED TISSUE IMMUNOFLUORESCENCE (T-CYCIF) IN HIGH-GRADE SEROUS OVARIAN CANCER
Journal Articles

Abstract AP14: POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER

Elizabeth H. Stover, Maria B. Baco, Ofir Cohen, Yvonne Li, Elizabeth Christie, Mukta Bagul, Amy Goodale, Yenarae Lee, Sasha Pantel, Matthew Rees, Guo Wei, Adam Presser, Ioannis Zervantonakis, Patrick Bhola, Jeremy Ryan, Jennifer Guerriero, Felice Liang, Andrew Cherniack, Federica Piccioni, Ursula A. Matulonis, David D. L. Bowtell, Anthony Letai, Kris Sarosiek, Levi Garraway, Cory M. Johannessen, Matthew Meyerson
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22_Supplement): AP14.
https://doi.org/10.1158/1557-3265.OVCASYMP18-AP14
Published: 15 November 2019
View article titled, Abstract AP14: POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER
Journal Articles

Abstract AP10: REAL-TIME ASSESSMENT OF HGSC DNA DAMAGE REPAIR DEFECTS AND DEFECT-INDUCED RESPONSE TO THERAPY IN OVARIAN CANCER ORGANOIDS

Sarah J. Hill, Brennan Decker, Emma A. Roberts, Chunyu Yang, Neil S. Horowitz, Michael G. Muto, Michael J. Worley, Jr., Colleen M. Feltmate, Marisa R. Nucci, Elizabeth M. Swisher, Ryuji Morizane, Bose Kochupurakkal, Khanh T. Do, Panagiotis Konstantinopoulos, Joyce F. Liu, Joseph V. Bonventre, Ursula A. Matulonis, Geoffrey I. Shapiro, Ross S. Berkowitz, Christopher P. Crum, Alan D. D'Andrea
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22_Supplement): AP10.
https://doi.org/10.1158/1557-3265.OVCASYMP18-AP10
Published: 15 November 2019
View article titled, Abstract AP10: REAL-TIME ASSESSMENT OF HGSC DNA DAMAGE REPAIR DEFECTS AND DEFECT-INDUCED RESPONSE TO THERAPY IN OVARIAN CANCER ORGANOIDS
Journal Articles

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

Kalindi Parmar, Bose S. Kochupurakkal, Jean-Bernard Lazaro, Zhigang C. Wang, Sangeetha Palakurthi, Paul T. Kirschmeier, Chunyu Yang, Larissa A. Sambel, Anniina Färkkilä, Elizaveta Reznichenko, Hunter D. Reavis, Connor E. Dunn, Lee Zou, Khanh T. Do, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Joyce F. Liu, Alan D. D'Andrea, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6127–6140.
https://doi.org/10.1158/1078-0432.CCR-19-0448
Published: 15 October 2019
View article titled, The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Open the PDF for The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition in another window
Includes: Supplementary data
Journal Articles

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine

Ursula A. Matulonis, Michael J. Birrer, David M. O'Malley, Kathleen N. Moore, Jason Konner, Lucy Gilbert, Lainie P. Martin, Todd M. Bauer, Amit M. Oza, Karim Malek, Jan Pinkas, Stella K. Kim
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (6): 1727–1736.
https://doi.org/10.1158/1078-0432.CCR-18-2474
Published: 15 March 2019
View article titled, Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine
Open the PDF for Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine in another window
Journal Articles

PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey

Panagiotis A. Konstantinopoulos, Ursula A. Matulonis
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17): 4062–4065.
https://doi.org/10.1158/1078-0432.CCR-18-1314
Published: 04 September 2018
View article titled, PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey
Open the PDF for PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey in another window
Journal Articles

Abstract A04: Profiling DNA damage repair and immunophenotypes in BRCA1/2 mutated high-grade serous ovarian cancers

Anniina Farkkila, Bose Kochupurakkal, Brooke E. Howitt, Kyle C. Strickland, Dipanjan Chowdhury, Geoffrey Shapiro, Evisa Gjini, Scott J. Rodig, Ursula A. Matulonis, Panagiotis Konstantinopoulos, Alan D. D’Andrea
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15_Supplement): A04.
https://doi.org/10.1158/1557-3265.OVCA17-A04
Published: 01 August 2018
View article titled, Abstract A04: Profiling DNA damage repair and immunophenotypes in BRCA1/2 mutated high-grade serous ovarian cancers
Journal Articles

Abstract IA01: PARP inhibitors as single agents and in combinations for ovarian cancer: What lies ahead?

Ursula A. Matulonis
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15_Supplement): IA01.
https://doi.org/10.1158/1557-3265.OVCA17-IA01
Published: 01 August 2018
View article titled, Abstract IA01: PARP inhibitors as single agents and in combinations for ovarian cancer: What lies ahead?
Journal Articles

Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer

Douglass W. Tucker, Christopher R. Getchell, Eric T. McCarthy, Anders W. Ohman, Naoko Sasamoto, Shuyun Xu, Joo Yeon Ko, Mamta Gupta, Amy Shafrir, Jamie E. Medina, Jonathan J. Lee, Lauren A. MacDonald, Ammara Malik, Kathleen T Hasselblatt, Wenjing Li, Hong Zhang, Samuel J. Kaplan, George F. Murphy, Michelle S. Hirsch, Joyce F. Liu, Ursula A. Matulonis, Kathryn L. Terry, Christine G. Lian, Daniela M. Dinulescu
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (6): 1389–1401.
https://doi.org/10.1158/1078-0432.CCR-17-1958
Published: 14 March 2018
View article titled, Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer
Open the PDF for Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract NTOC-112: GENOMIC SCARS AND CLINICAL RESPONSE TO COMBINATION THERAPY OF PARP AND ANGIOGENESIS INHIBITORS IN OVARIAN CANCER

Zhigang C. Wang, Nicolai Juul Birkbak, William T. Barry, Thomas M. Roberts, Eric P. Winer, J Dirk Iglehart, Ursula A. Matulonis, S. Percy Ivy, Joyce F. Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): NTOC-112.
https://doi.org/10.1158/1557-3265.OVCASYMP16-NTOC-112
Published: 31 May 2017
View article titled, Abstract NTOC-112: GENOMIC SCARS AND CLINICAL RESPONSE TO COMBINATION THERAPY OF PARP AND ANGIOGENESIS INHIBITORS IN OVARIAN CANCER
Journal Articles

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics

Joyce F. Liu, Sangeetha Palakurthi, Qing Zeng, Shan Zhou, Elena Ivanova, Wei Huang, Ioannis K. Zervantonakis, Laura M. Selfors, Yiping Shen, Colin C. Pritchard, Mei Zheng, Vilmos Adleff, Eniko Papp, Huiying Piao, Marian Novak, Susan Fotheringham, Gerburg M. Wulf, Jessie English, Paul T. Kirschmeier, Victor E. Velculescu, Cloud Paweletz, Gordon B. Mills, David M. Livingston, Joan S. Brugge, Ursula A. Matulonis, Ronny Drapkin
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (5): 1263–1273.
https://doi.org/10.1158/1078-0432.CCR-16-1237
Published: 28 February 2017
View article titled, Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
Open the PDF for Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics in another window
Includes: Supplementary data